Xovoltib Tablet contains afatinib dimaleate, a potent tyrosine kinase inhibitor for metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. It binds irreversibly to EGFR and other ErbB family receptors, blocking tumor cell growth (FDA label, Mayo Clinic).

Key Benefits & Uses

Xovoltib treats metastatic NSCLC with EGFR mutations such as S768I, L861Q, and G719X (FDA). It also serves as a second-line option for squamous NSCLC after platinum chemotherapy (Drugs.com). Clinical studies show it reduces tumor size and slows disease progression (PubMed).

How to Use

Take 40 mg orally once a day on an empty stomach, at least one hour before or two hours after a meal. Swallow tablets whole without chewing or crushing. If you miss a dose, take it as soon as you remember unless it is less than 12 hours before the next dose. Avoid grapefruit and grapefruit juice (Healthline).

Important Safety Information

Do not use Xovoltib if you are allergic to afatinib or any tablet ingredient. Monitor for severe diarrhea, skin reactions, or eye inflammation. Check liver and kidney function regularly. Use caution if you have a history of gastrointestinal perforations (Drugs.com, WebMD).

Common Side Effects

Common side effects include diarrhea, rash, dry skin, mouth sores, nausea, loss of appetite, and nail changes. Severe effects may include serious diarrhea, lung problems, liver dysfunction, or gastrointestinal perforation (Healthline).

Why Choose Xovoltib Tablet?

Xovoltib provides targeted therapy for EGFR mutation-positive NSCLC. It offers convenient once-daily dosing and a strong safety record. Clinical trials support its effectiveness, and the FDA approves its use (FDA, WHO).